scholarly journals The rate of hyperglycemia and ketosis with insulin degludec‐based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials

2019 ◽  
Vol 20 (3) ◽  
pp. 314-320 ◽  
Author(s):  
Nandu Thalange ◽  
Larry Deeb ◽  
Georgeanna Klingensmith ◽  
Denise R. Franco ◽  
Lars Bardtrum ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Detemir ◽  
Randomized Trials ◽  
Pediatric Patients ◽  
Insulin Degludec

scholarly journals Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK

2019 ◽  
Vol 7 (1) ◽  
pp. e000664 ◽  
Author(s):  
Nandu Thalange ◽  
Jens Gundgaard ◽  
Witesh Parekh ◽  
Deniz Tutkunkardas
Keyword(s):  
Type 1 Diabetes ◽  
Cost Analysis ◽  
Children And Adolescents ◽  
Annual Cost ◽  
Insulin Detemir ◽  
Cost Savings ◽  
Insulin Degludec ◽  
Age Group ◽  
The Uk

ObjectiveWith healthcare systems under increasing financial pressure from costs associated with diabetes care, it is important to assess which treatments provide clinical benefits and represent best value. This study evaluated the annual costs of insulin degludec (degludec) versus insulin detemir (IDet) in children and adolescents with type 1 diabetes (T1D) in the UK.Research design and methodsUsing data from a randomized, treat-to-target, non-inferiority trial—BEGIN YOUNG 1—annual costs with degludec versus IDet in children and adolescents aged 1–17 years with T1D were estimated, as costs of these insulins and hyperglycemia with ketosis events. Analyses by age group (1–5, 6–11 and 12–17 years) and scenario (no ketosis benefit, no dose benefit, hyperglycemia with ketones >0.6 and >3.0 mmol/L and the additional costs of twice-daily IDet in 64% of patients) were also performed.ResultsThe mean annual cost per patient was estimated as £235.16 for degludec vs £382.91 for IDet, resulting in an annual saving of £147.75 per patient. These substantial cost savings were driven by relative reductions in the frequency of hyperglycemia with ketosis and basal insulin dose with degludec versus IDet. Annual savings in favor of degludec were observed across each age group (£122.63, £140.59 and £172.50 for 1–5, 6–11 and 12–17 years age groups, respectively). Five scenario analyses further demonstrated the robustness of the results, which included no ketosis or dose benefits in favor of degludec.ConclusionsDegludec provides appreciable annual cost savings compared with IDet in children and adolescents with T1D in a UK setting. While a cost-effectiveness analysis could incorporate the health impact of treatment complications better than the present cost analysis, the strong generalizability of the data from this study suggests that degludec can help healthcare providers to maximize health outcomes despite increasingly stringent budgets.

scholarly journals Impact of Insulin Degludec Therapy on Glycemia Variability, Glycated Hemoglobin, and Time in Range in Paediatric Patients with Type 1 Diabetes Mellitus

Doctor Ru ◽  
2021 ◽  
Vol 20 (3) ◽  
pp. 40-44
Author(s):  
V.V. Platonov ◽  
◽  
E.M. Patrakeeva ◽  
Yu.L. Skorodok ◽  
E.V. Plotnikova ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Basal Insulin ◽  
Insulin Detemir ◽  
Glycated Hemoglobin ◽  
Insulin Degludec ◽  
Time In Range ◽  
Group 2

Study Objective: To compare glycemia variability (GV), glycated hemoglobin (HbA1c) and time in range in paediatric patients with type 1 diabetes mellitus (DM1) with various baseline GV after the change from basal insulin detemir to insulin degludec. Study Design: Non-randomised controlled study. Materials and Methods. We examined 30 children with DM1 aged 5 to 17 years; duration of disease was at least 1 year. Patients were divided into two groups, depending on the rate of the coefficient of variability (CV): ≤ 36% — group 1, > 36% — group 2. Time in range, time above range and time below range as well as CV were evaluated on the basis of the standard outpatient glucose profile using glycemia monitoring programme with periodic scanning (flash monitoring) before and after the change of basal insulin. Study Results. After group 2 patients switched from insulin detemir to insulin degludec, we noted increased time in range (from 40.3 ± 11.5% to 62.4 ± 6.7%; р < 0.001), reduced time above range (from 53.7 ± 10.7% to 34.1 ± 6.6%; р < 0.001), CV (from 43.2 ± 5.4% to 37.0 ± 3.3%; р = 0.05), and HbA1c (from 9.4 ± 1.5% to 7.5 ± 0.7%; р < 0.05), with no time below range. Conclusion. In children with DM1 who were treated with basal insulin detemir and had high GV, switching to insulin degludec allows significant improvement of metabolic control without the risk of hypoglycaemia. Keywords: type 1 diabetes mellitus, glycemia variability, degludec, coefficient of variation, time in range.

Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial

2015 ◽  
Vol 18 (1) ◽  
pp. 96-99 ◽  
Author(s):  
M. Davies ◽  
T. Sasaki ◽  
J. L. Gross ◽  
G. Bantwal ◽  
Y. Ono ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Detemir ◽  
Insulin Degludec ◽  
Treat To Target ◽  
Target Trial

Arginine metabolism and gut microbiota changes in pediatric patients with type 1 diabetes

2020 ◽  
Author(s):  
Elena Aghajanova ◽  
Arthur Melkonyan ◽  
Nina Alchujyan ◽  
Bayburdyan Gayane ◽  
Margarita Hovhannisyan ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Gut Microbiota ◽  
Pediatric Patients ◽  
Arginine Metabolism

1290-P: Gut Microbiota in New-Onset Pediatric Patients with Type 1 Diabetes: Machine Learning Algorithms to Classify Microorganisms Disease-Linked

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1290-P
Author(s):  
GIUSEPPE D’ANNUNZIO ◽  
ROBERTO BIASSONI ◽  
MARGHERITA SQUILLARIO ◽  
ELISABETTA UGOLOTTI ◽  
ANNALISA BARLA ◽  
...  
Keyword(s):  
Machine Learning ◽  
Type 1 Diabetes ◽  
Gut Microbiota ◽  
Pediatric Patients ◽  
Learning Algorithms ◽  
Machine Learning Algorithms ◽  
New Onset

270-OR: Nocturnal Hypoglycemia with Insulin Degludec and Glargine U100 in Patients with Type 1 Diabetes Prone to Severe Nocturnal Hypoglycemia (HypoDeg): A CGM Substudy

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 270-OR
Author(s):  
JULIE M. BRØSEN ◽  
RIKKE M. AGESEN ◽  
AMRA CIRIC ALIBEGOVIC ◽  
HENRIK U. ANDERSEN ◽  
PETER GUSTENHOFF ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Degludec ◽  
Nocturnal Hypoglycemia

269-OR: Effect of Insulin Degludec on Frequency of Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia: The HypoDeg Trial

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 269-OR
Author(s):  
RIKKE M. AGESEN ◽  
AMRA CIRIC ALIBEGOVIC ◽  
HENRIK U. ANDERSEN ◽  
PETER GUSTENHOFF ◽  
TROELS K. HANSEN ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Severe Hypoglycemia ◽  
Insulin Degludec
Sign in / Sign up

Export Citation Format

Share Document